# EDGAR Filing Document

**Accession Number:** 0001612042
**File Stem:** 0001610717-26-000106
**Filing Date:** 2026-3
**Character Count:** 8977
**Document Hash:** 66d55d56db3385ab204c7e2018ae0d16
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001610717-26-000106.hdr.sgml**: 20260415

**ACCESSION NUMBER**: 0001610717-26-000106

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shu Aimee
- **CENTRAL INDEX KEY:** 0002048323

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36815
- **FILM NUMBER:** 26770973

**MAIL ADDRESS:**
- **STREET 1:** C/O ASCENDIS PHARMA A/S
- **STREET 2:** TUBORG BOULEVARD 12
- **CITY:** HELLERUP
- **STATE:** G7
- **ZIP:** DK-2900
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ascendis Pharma A/S
- **CENTRAL INDEX KEY:** 0001612042
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG BOULEVARD 12
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7
- **BUSINESS PHONE:** 45 70 22 22 44

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TUBORG BOULEVARD 12
- **CITY:** HELLERUP
- **PROVINCE COUNTRY:** G7

## Ex-24

```

                               POWER OF ATTORNEY

     With  respect  to  holdings  of  and  transactions  in securities issued by
Ascendis  Pharma  A/S  (the  "Company"),  the undersigned hereby constitutes and
appoints  the  individuals  named  on  SCHEDULE  A attached hereto and as may be
amended  from  time  to  time, or any of them signing singly, with full power of
substitution  and  resubstitution,  to  act as the undersigned's true and lawful
attorney-in-fact to:

     1.    execute for and on behalf of the undersigned, Schedules 13D and 13G
         in  accordance  with Section 13 of the Securities Exchange Act of 1934,
         as  amended  (the  "Exchange Act"), and the rules thereunder, and Forms
         3,  4,  and 5 in accordance with Section 16 of the Exchange Act and the
         rules  thereunder,  and Notices of Proposed Sale of Securities Pursuant
         to  Rule  144 ("Form 144"), in accordance with the requirements of Rule
         144  under  the  Securities  Act  of  1933, as amended (the "Securities
         Act"); and

     2.    do and perform any and all acts for and on behalf of the undersigned
         which  may  be  necessary or desirable to complete and execute any such
         Schedule  13D,  Schedule  13G,  Form  3,  Form 4, Form 5, and Form 144,
         complete  and  execute  any  amendment  or  amendments  thereto, and to
         timely  file  such  Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5,
         and  Form  144,  as  applicable,  and  any  amendment thereto, with the
         United  States  Securities  and  Exchange  Commission  and  any  stock
         exchange or similar authority.

     The  undersigned hereby grants to each such attorney-in-fact full power and
     authority  to  do  and  perform  any  and  every  act  and thing whatsoever
     requisite,  necessary,  or  proper to be done in the exercise of any of the
     rights  and  powers herein granted, as fully to all intents and purposes as
     the  undersigned  might  or could do if personally present, with full power
     of  substitution  and  resubstitution  or  revocation, hereby ratifying and
     confirming  all  that  such  attorney-in-fact,  or  such  attorneys-in-fact
     substitute  or substitutes, shall lawfully do or cause to be done by virtue
     of this Power of Attorney and the rights and powers herein granted.

     The  undersigned  acknowledges  that  the  foregoing  attorneys-in-fact, in
serving  in  such  capacity at the request of the undersigned, are not assuming,
nor  is  the  Company  assuming,  any  of  the undersigned's responsibilities to
comply  with  Section  13  and Section 16 of the Exchange Act, or Rule 144 under
the Securities Act.

     This  Power  of  Attorney  shall  remain in full force and effect until the
undersigned  is  no longer required to file any Schedule 13D, Schedule 13G, Form
3,  Form  4,  Form 5, and Form 144 with respect to the undersigned's holdings of
and  transactions in securities issued by the Company, unless earlier revoked by
the  undersigned  in  a  signed  writing  delivered  to  the  foregoing
attorneys-in-fact.

     IN  WITNESS  WHEREOF,  the undersigned has caused this Power of Attorney to
     be executed as of this 18th day of March, 2026.

                                        /s/ Aimee Shu

                                   Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and
                                 Resubstitution

Jan Mikkelsen, President and Chief Executive Officer
Scott Smith, Executive Vice President, Chief Financial Officer
Michael Wolff Jensen, Executive Vice President, Chief Legal Officer
Mads Bodenhoff, Senior Vice President, Head of Finance and Principal Accounting
Officer
Birgitte Bogelund-Arvidsen, Senior Director, Equity Compensation
Anders Carstensen, Head of Corporate and Legal Transactions

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shu Aimee<br><sub>(Last) (First) (Middle)</sub><br>C/O ASCENDIS PHARMA A/S<br>TUBORG BOULEVARD 12<br><sub>(Street)</sub><br>HELLERUP,  DK-2900<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Ascendis Pharma A/S [ ASND ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP & Chief Medical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares<sup>(1)</sup> | 0 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(2)</sup> | <sup>(2)</sup> | Ordinary Shares | 6532 | <sup>(3)</sup> | D |  |
| Restricted Stock Units | <sup>(4)</sup> | <sup>(4)</sup> | Ordinary Shares | 3197 | <sup>(3)</sup> | D |  |
| Restricted Stock Units | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 9552 | <sup>(3)</sup> | D |  |

---

### Footnotes:

(1) Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

(2) The restricted stock units vest on March 1, 2027 and have no expiration date.

(3) Each restricted stock unit represents a contingent right to receive one ADS.

(4) The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

(5) The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

**Signature:** /s/ Michael Wolff Jensen as attorney-in-fact for Aimee Shu  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**